ReviewInternational journal of clinical oncology2008
Current research topics in endocrine therapy for breast cancer.
Review in International journal of clinical oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Clinical significance of serum PSA in breast cancer patients.BMC cancer · 2019Article
- RET in breast cancer: pathogenic implications and mechanisms of drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Human 3β-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations.Cancer medicine · 2016Article
- Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.Molecular & cellular proteomics : MCP · 2015Article
- Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.Acta pharmacologica Sinica · 2015Article
- Estrogen receptor α-coupled Bmi1 regulation pathway in breast cancer and its clinical implications.BMC cancer · 2014Article
- Activation of rapid oestrogen signalling in aggressive human breast cancers.EMBO molecular medicine · 2012Article
- Development of ti-coated ferromagnetic needle, adaptable for ablation cancer therapy by high-frequency induction heating.Journal of functional biomaterials · 2012Article
- Article
- δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer.PloS one · 2012Article
- Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.Breast cancer research : BCR · 2011Article
- CUEDC2: an emerging key player in inflammation and tumorigenesis.Protein & cell · 2011Review
- ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.Molecular cancer therapeutics · 2011Article
- Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.Nature medicine · 2011Article
- Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.PloS one · 2011Article
- ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy.Oncology letters · 2010Article
- Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.PloS one · 2010Article
- FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.Oncogene · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are large-scale molecular differences between estrogen receptor (ER)-positive and ER-negative breast cancers. Endocrine therapy has become the most important treatment option for women with ER-positive breast cancer, and approximately 70% of primary breast cancers express ERalpha. Endocrine therapy has provided meaningful advances in breast cancer treatment and prevention. However, some patients continue to develop recurrence and die of the disease. New insights into ER biology and progress in the understanding of resistance mechanisms are generating tremendous promise for new therapeutic opportunities to target resistance and improve disease outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.